Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00898924

Enrollment

Registered

2009-05-12

Start date

2005-11-30

Completion date

2010-07-31

Last updated

2016-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer

Brief summary

RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.

Detailed description

OBJECTIVES: * Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106. * Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients. OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.

Interventions

GENETICmolecular diagnostic method

GENETICmutation analysis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Eligible patients had histologic documentation of un- treated stage III NSCLC. 2. Radiation oncologist confirmation was required that radiation could be given per protocol. 3. Eastern Cooperative Group Criteria Performance Status of 0 to 2 4. Tumor specimen paraffin block or unstained slides and standard initial laboratory tests 5. Signed institutional review board-approved, protocol-specific in- formed consent in accordance with federal and institutional guidelines

Exclusion criteria

1\. Patients with scalene, supraclavicular, or contralateral hilar lymph node involvement, or direct invasion of the vertebral body or with a pleural effusion were ineligible.

Design outcomes

Primary

Measure	Time frame
Overall survival	Up to 3 years
Progression free survival	Up to 3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026